Daiichi Sankyo Company, Limited

Sankyo Company, Limited

Osamu Ando

Tomio Kimura

Nobuyuki Ohkawa

Atsuhiro Sugidachi

Takayoshi Nagasaki

Mutsuo Nakajima

Takeshi Kinoshita

Shuji Takahashi

Kiyoshi Hamano

Hideyuki Haruyama

Ryuzo Enokita

Akira Sato

Yasuyuki Takamatsu

A compound of formula (I) Wherein X, Y, ring A, ring B, l, m, R, R, Rand Rare as defined herein, to supress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-&#x3b1;, pharmacologically acceptable salts therefor, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and/or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation.

Substituted cycloalkene derivative

5-Amino-1-(hydroxymethyl)cyclopentane-1,2,3,4-tetraol and 2-amino-4-(hydroxymethyl)-3a,5,6,6a-tetrahydro-4H-cyclopent[d]oxazole-4,5, 6-triol, which have the ability to inhibit the activity of sugar hydrolases, especially .beta.-glucosidase and sucrase and can thus be used for the treatment and prophylaxis of tumorous conditions, AIDS, diabetes and obesity, can be prepared by hydrolysis of trehazolin. 2-Amino-4-(hydroxymethyl)-3a,5,6,6a-tetrahydro-4H-cyclopent[d]oxazole-4,5, 6-triol can also be prepared by fermentation using newly isolated strains Micromonospora sp. SANK 62390, FERM BP-3521 and Amycolatopsis sp. SANK 60791, FERM BP-3513.

Polyhydroxycyclopentane derivatives, their preparation and their

Growing community of inventors

Tokyo, Japan

Osamu Ando